Medicare’s telehealth flexibilities get most of the headlines, and Congress has extended many of them through December 31, 2027. That deadline is real, but it is not the one keeping compliance officers up right now. The immediate pressure point lands in roughly 90 days: December 31, 2026, when the DEA’s fourth and final temporary extension of pandemic-era teleprescribing rules expires.
The DEA has been developing its permanent special registration framework for years, and the federal regulatory agenda continues to point to action in November 2026. That timetable is aggressive. The temporary federal telemedicine prescribing flexibilities that have governed much of remote controlled-substance prescribing since the pandemic expire December 31, 2026, meaning clinicians, pharmacies, and telehealth companies could have only weeks between the rule’s publication and the expiration of the framework they have relied upon for years.
What hangs in the balance is significant. Under the current extension, a DEA-registered practitioner may prescribe Schedule II through V controlled substances by telehealth without a prior in-person evaluation. Separately, a finalized federal rule allows patients to receive buprenorphine for opioid use disorder via audio-video or audio-only telehealth for up to six months without a prior in-person visit. Strip the broader extension away without a workable replacement, and the patient base of every direct-to-consumer mental health, addiction treatment, and ADHD platform shrinks overnight.
Investors in companies like Hims & Hers should read the fine print carefully. The company posted $753 million in Q2 2026 revenue, up 38% year over year, and raised full-year guidance to a range of $3.1 billion to $3.3 billion. The FTC is also suing Hims & Hers, adding another regulatory layer on top of the DEA question. The company’s own SEC filings acknowledge the risk plainly: the DEA has indicated its intention to finalize permanent regulations before the current extension expires, but whether the outcome is a permanent rule, a further extension, or a lapse in authority is uncertain, and if new rules impose additional requirements, telehealth service providers may need to modify their operations to comply, increasing costs or reducing the availability of controlled substances on their platforms.
The proposed permanent framework would not merely replace the temporary rules with the same terms. The proposed rule would establish a permanent framework for telehealth prescribing of controlled substances without a prior in-person evaluation, including new registration, recordkeeping, reporting, and identity-verification requirements, and would regulate certain direct-to-consumer telehealth platforms as intermediaries. That last phrase matters. Treating platforms as intermediaries rather than passive technology vendors shifts compliance obligations and potentially liability in ways that would raise operating costs across the sector.
The Medicare cliff on the other end of 2027 adds a second pressure track. The broader flexibilities remain temporary, and the same policy cliff that caused disruption in 2025 could return in late 2027 if Congress does not act on permanent legislation. The 2025 experience illustrated what disruption looks like in numbers: after a lapse in Medicare telehealth flexibilities in September 2025, HHS reported a 24% drop in telemedicine visits among fee-for-service beneficiaries.
For investors, the sector faces a choice point. Mental health practices carry the most exposure, with some now delivering 40% to 60% of visits via telehealth. If restrictions return, those patients do not automatically convert to in-person visits; many will not come in at all, especially in areas with limited provider access.
The companies that survive both deadlines intact will likely be those with diversified revenue beyond controlled-substance prescribing and the compliance infrastructure to absorb new registration requirements quickly. Those built on a single regulatory waiver that Congress or the DEA could close in November are the ones to watch carefully between now and year-end.
